229 related articles for article (PubMed ID: 38334635)
1. Blastic Plasmacytoid Dendritic Cell Neoplasm: A Comprehensive Review of the Disease, Central Nervous System Presentations, and Treatment Strategies.
Mehra S; Taylor J
Cells; 2024 Jan; 13(3):. PubMed ID: 38334635
[TBL] [Abstract][Full Text] [Related]
2. Frontline Hyper-CVAD Plus Venetoclax for Pediatric Blastic Plasmacytoid Dendritic Cell Neoplasm.
He J; Garcia MB; Connors JS; Nuñez CA; Quesada AE; Gibson A; Roth M; Cuglievan B; Pemmaraju N; McCall D
J Pediatr Hematol Oncol; 2023 Nov; 45(8):e1001-e1004. PubMed ID: 37661300
[TBL] [Abstract][Full Text] [Related]
3. Blastic plasmacytoid dendritic cell neoplasm frequently shows occult central nervous system involvement at diagnosis and benefits from intrathecal therapy.
Martín-Martín L; Almeida J; Pomares H; González-Barca E; Bravo P; Giménez T; Heras C; Queizán JA; Pérez-Ceballos E; Martínez V; Alonso N; Calvo C; Álvarez R; Caballero MD; Orfao A
Oncotarget; 2016 Mar; 7(9):10174-81. PubMed ID: 26840087
[TBL] [Abstract][Full Text] [Related]
4. Blastic Plasmacytoid Dendritic Cell Neoplasm.
Jain A; Sweet K
J Natl Compr Canc Netw; 2023 May; 21(5):515-521. PubMed ID: 37156483
[TBL] [Abstract][Full Text] [Related]
5. Diagnostic management of blastic plasmacytoid dendritic cell neoplasm (BPDCN) in close interaction with therapeutic considerations.
Shumilov E; Mazzeo P; Ghandili S; Künstner A; Weidemann S; Banz Y; Ströbel P; Pollak M; Kolloch L; Beltraminelli H; Kerkhoff A; Mikesch JH; Schliemann C; Haase D; Wulf G; Legros M; Lenz G; Feldmeyer L; Pabst T; Witte H; Gebauer N; Bacher U
Ann Hematol; 2024 May; 103(5):1587-1599. PubMed ID: 38194088
[TBL] [Abstract][Full Text] [Related]
6. Tagraxofusp followed by combined azacitidine and venetoclax in blastic plasmacytoid dendritic cell neoplasm: A case report and literature review.
Samhouri Y; Ursu S; Dutton N; Tanvi V; Fazal S
J Oncol Pharm Pract; 2021 Jun; 27(4):990-995. PubMed ID: 32847479
[TBL] [Abstract][Full Text] [Related]
7. Liposomal Daunorubicin and Cytarabine, a Potential Therapy for Blastic Plasmacytoid Dendritic Cell Neoplasm.
Ashok Kumar P; Ombada M; Pemmasani G; Tambe A; Banki K; Gentile T
J Investig Med High Impact Case Rep; 2022; 10():23247096221127114. PubMed ID: 36341907
[TBL] [Abstract][Full Text] [Related]
8. Blastic plasmacytoid dendritic cell neoplasm: diagnosis, manifestations, and treatment.
Sweet K
Curr Opin Hematol; 2020 Mar; 27(2):103-107. PubMed ID: 31972688
[TBL] [Abstract][Full Text] [Related]
9. Clinical features and treatment outcomes of blastic plasmacytoid dendritic cell neoplasm: a single-center experience in Korea.
Kim HS; Kim HJ; Kim SH; Choi JY; Ko YH; Kim WS; Jung CW; Kim SJ
Korean J Intern Med; 2017 Sep; 32(5):890-899. PubMed ID: 28870016
[TBL] [Abstract][Full Text] [Related]
10. Blastic plasmacytoid dendritic cell neoplasm: emerging developments and special considerations for 2023.
Pemmaraju N; Kantarjian H
Clin Adv Hematol Oncol; 2023 May; 21(5):257-264. PubMed ID: 37145496
[TBL] [Abstract][Full Text] [Related]
11. Novel Therapeutic Approaches in Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN): Era of Targeted Therapy.
Wilson NR; Konopleva M; Khoury JD; Pemmaraju N
Clin Lymphoma Myeloma Leuk; 2021 Nov; 21(11):734-740. PubMed ID: 34226167
[TBL] [Abstract][Full Text] [Related]
12. Evaluating tagraxofusp for the treatment of blastic plasmacytoid dendritic cell neoplasm (BPDCN).
Wilson NR; Pemmaraju N
Expert Opin Pharmacother; 2022 Mar; 23(4):431-438. PubMed ID: 35060807
[TBL] [Abstract][Full Text] [Related]
13. Blastic plasmacytoid dendritic cell neoplasm (BPDCN): A promising future in the era of targeted therapeutics.
Adimora IJ; Wilson NR; Pemmaraju N
Cancer; 2022 Aug; 128(16):3019-3026. PubMed ID: 35726525
[TBL] [Abstract][Full Text] [Related]
14. Low-dose venetoclax combined with azacitidine for blastic plasmacytoid dendritic cell neoplasm: a case report and literature review.
Wang Q; Zhao Y; Zang X; Zhou G; Liu Y; Feng Q; Li X; Wang W; Dong X; Liu X; Peng J; Liu C
Ann Hematol; 2024 Mar; 103(3):999-1005. PubMed ID: 38285081
[TBL] [Abstract][Full Text] [Related]
15. Recent Advances in the Biology and CD123-Directed Treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm.
Pemmaraju N; Deconinck E; Mehta P; Walker I; Herling M; Garnache-Ottou F; Gabarin N; Campbell CJV; Duell J; Moshe Y; Mughal T; Mohty M; Angelucci E
Clin Lymphoma Myeloma Leuk; 2024 Apr; 24(4):e130-e137. PubMed ID: 38267355
[TBL] [Abstract][Full Text] [Related]
16. Characteristics and outcomes of patients with blastic plasmacytoid dendritic cell neoplasm treated with frontline HCVAD.
Pemmaraju N; Wilson NR; Garcia-Manero G; Sasaki K; Khoury JD; Jain N; Borthakur G; Ravandi F; Daver N; Kadia T; DiNardo C; Jabbour E; Pierce S; Qazilbash M; Konopleva M; Kantarjian H
Blood Adv; 2022 May; 6(10):3027-3035. PubMed ID: 35061885
[TBL] [Abstract][Full Text] [Related]
17. Treatment of patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN): focus on the use of tagraxofusp and clinical considerations.
Pemmaraju N; Madanat YF; Rizzieri D; Fazal S; Rampal R; Mannis G; Wang ES; Foran J; Lane AA
Leuk Lymphoma; 2024 May; 65(5):548-559. PubMed ID: 38391126
[TBL] [Abstract][Full Text] [Related]
18. Blastic plasmacytoid dendritic cell neoplasm (BPDCN): a rare entity.
Lim MS; Lemmert K; Enjeti A
BMJ Case Rep; 2016 Jan; 2016():. PubMed ID: 26791132
[TBL] [Abstract][Full Text] [Related]
19. Unique presentation of blastic plasmacytoid dendritic cell neoplasm: a single-center experience and literature review.
Paluri R; Nabell L; Borak S; Peker D
Hematol Oncol; 2015 Dec; 33(4):206-11. PubMed ID: 24850172
[TBL] [Abstract][Full Text] [Related]
20. The advances in therapy of blastic plasmacytoid dendritic cell neoplasm.
Kerr D; Sokol L
Expert Opin Investig Drugs; 2018 Sep; 27(9):733-739. PubMed ID: 30118336
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
